+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ulcerative Colitis Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 181 Pages
  • April 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309857

Global Ulcerative Colitis Therapeutics Market to Reach $9.5 Billion by 2030

The global market for Ulcerative Colitis Therapeutics estimated at US$6.7 Billion in the year 2022, is projected to reach a revised size of US$9.5 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2022-2030. Oral, one of the segments analyzed in the report, is projected to record 4% CAGR and reach US$5.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Injectables segment is readjusted to a revised 5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 4.2% CAGR

The Ulcerative Colitis Therapeutics market in the U.S. is estimated at US$2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 4.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 3.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Select Competitors (Total 16 Featured) -

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Amgen, Inc.
  • Arena Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Avaxia Biologics, Inc.
  • BioLineRx Ltd.
  • Celgene Corporation
  • Cosmo Pharmaceuticals NV
  • EA Pharma Co., Ltd.
  • Eisai Co., Ltd.
  • Ferring Pharmaceuticals
  • Galapagos NV
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hutchison MediPharma Limited
  • Immune Pharmaceuticals, Inc.
  • InDex Pharmaceuticals Holding AB
  • Janssen Biotech, Inc.
  • Kaken Pharmaceutical Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • Lipid Therapeutics GmbH
  • Meda AB
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Mochida Pharmaceutical Co., Ltd.
  • Morphotek, Inc.
  • Nestle SA
  • Pfizer, Inc.
  • Procter & Gamble Company, The
  • Qu Biologics Inc.
  • Salix Pharmaceuticals, Inc.
  • Shield Therapeutics PLC
  • Shire Pharmaceuticals, Inc.
  • Sterna Biologicals GmbH & Co. KG
  • Takeda Pharmaceuticals Company Ltd.
  • Tillotts Pharma AG
  • TopiVert Ltd.
  • UCB SA
  • Zeria Pharmaceutical Co., Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Ulcerative Colitis Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Ulcerative Colitis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 8: World Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 9: World Historic Review for Ulcerative Colitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 10: World 16-Year Perspective for Ulcerative Colitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 12: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 13: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 15: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 16: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Mild UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 18: World Historic Review for Mild UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: World 16-Year Perspective for Mild UC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Moderate UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 21: World Historic Review for Moderate UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: World 16-Year Perspective for Moderate UC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Severe UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 24: World Historic Review for Severe UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: World 16-Year Perspective for Severe UC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 26: USA Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: USA Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: USA 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 29: USA Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: USA Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: USA 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 32: USA Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: USA Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: USA 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • CANADA
  • Table 35: Canada Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Canada Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Canada 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 38: Canada Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: Canada 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 41: Canada Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Canada Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Canada 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • JAPAN
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 44: Japan Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Japan 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 47: Japan Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Japan Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Japan 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 50: Japan Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Japan Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: Japan 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • CHINA
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 53: China Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: China Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: China 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 56: China Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: China Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: China 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 59: China Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: China Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: China 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • EUROPE
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 62: Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Europe Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 64: Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 65: Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: Europe Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 67: Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 68: Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 69: Europe Historic Review for Ulcerative Colitis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 70: Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 71: Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: Europe Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 73: Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • FRANCE
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 74: France Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: France Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 76: France 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 77: France Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: France Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 79: France 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 80: France Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: France Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 82: France 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • GERMANY
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 83: Germany Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: Germany Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 85: Germany 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 86: Germany Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Germany Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 88: Germany 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 89: Germany Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Germany Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 91: Germany 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • ITALY
  • Table 92: Italy Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Italy Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 94: Italy 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 95: Italy Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 96: Italy Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 97: Italy 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 98: Italy Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 99: Italy Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 100: Italy 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 101: UK Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 102: UK Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 103: UK 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 104: UK Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 105: UK Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 106: UK 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 107: UK Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 108: UK Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 109: UK 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 110: Rest of Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 111: Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 112: Rest of Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 113: Rest of Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 114: Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 115: Rest of Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 116: Rest of Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 117: Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 118: Rest of Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 119: Asia-Pacific Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 120: Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 121: Asia-Pacific 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2023 & 2030
  • Table 122: Asia-Pacific Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 123: Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 124: Asia-Pacific 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2023 & 2030
  • Table 125: Asia-Pacific Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 126: Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 127: Asia-Pacific 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
  • REST OF WORLD
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Amgen, Inc.
  • Arena Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Avaxia Biologics, Inc.
  • BioLineRx Ltd.
  • Celgene Corporation
  • Cosmo Pharmaceuticals NV
  • EA Pharma Co., Ltd.
  • Eisai Co., Ltd.
  • Ferring Pharmaceuticals
  • Galapagos NV
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hutchison MediPharma Limited
  • Immune Pharmaceuticals, Inc.
  • InDex Pharmaceuticals Holding AB
  • Janssen Biotech, Inc.
  • Kaken Pharmaceutical Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • Lipid Therapeutics GmbH
  • Meda AB
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Mochida Pharmaceutical Co., Ltd.
  • Morphotek, Inc.
  • Nestle SA
  • Pfizer, Inc.
  • Procter & Gamble Company, The
  • Qu Biologics Inc.
  • Salix Pharmaceuticals, Inc.
  • Shield Therapeutics PLC
  • Shire Pharmaceuticals, Inc.
  • Sterna Biologicals GmbH & Co. KG
  • Takeda Pharmaceuticals Company Ltd.
  • Tillotts Pharma AG
  • TopiVert Ltd.
  • UCB SA
  • Zeria Pharmaceutical Co., Ltd.

Table Information